VERORAB

Indications

• Cancer (e.g., leukemia, lymphoma)
• Autoimmune diseases (e.g., lupus, rheumatoid arthritis)
• Cardiovascular diseases (e.g., myocardial infarction)
• Neurological disorders (e.g., Parkinson's disease, multiple sclerosis)
• Orthopedic conditions (e.g., osteoarthritis)
• Genetic disorders (e.g., cystic fibrosis)

Dosage

Children: Dosage varies widely based on the cell type and condition being treated. Refer to specific treatment protocols and guidelines.

Adults: Dosage varies widely based on the cell type and condition being treated. Refer to specific treatment protocols and guidelines.

Mechanism of action

Cell therapies can function through several mechanisms, including differentiation into specific cell types, secretion of bioactive factors that promote tissue repair, and modulation of the immune response. For example, in the case of stem cells, they can migrate to sites of injury and contribute to tissue regeneration and repair.

Pharmacodynamics

The pharmacodynamics of cell therapy depend on the type of cells used and their intended purpose. For immune cell therapies, such as CAR T-cell therapy, the activated T-cells seek out and destroy cancer cells. In regenerative medicine, stem cells can differentiate into various cell types, potentially restoring normal function in damaged tissues. The therapeutic effects may also be mediated through paracrine signaling, where the cells release signaling molecules that enhance healing processes.

Pharmacokinetics

The pharmacokinetics of cell therapies include factors such as cell migration, engraftment, and survival within the host. After administration, cells may migrate to the target tissue, where they ideally engraft and proliferate. The lifespan of administered cells can vary significantly depending on the cell type and the patient's immune response. For example, some immune cells may have a short half-life, while stem cells may persist longer and contribute to ongoing tissue repair.

Pregnancy

There is limited data on the safety of this drug during pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering this drug to breastfeeding mothers, as it may pass into breast milk and affect the nursing infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Pneumonia caused by Gram-positive bacteria
• Skin and soft tissue infections
• Infections caused by vancomycin-resistant Enterococcus
• Bacteremia due to Staphylococcus aureus

Dosage

Children: For children, the dosage should be determined based on the specific infection and must be referred to the BNF for Children for precise dosing.

Adults: The usual adult dosage for linezolid is 600 mg taken orally or intravenously every 12 hours.

Mechanism of action

Linezolid inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit, preventing the formation of the initiation complex necessary for protein synthesis. This action disrupts the production of essential proteins required for bacterial growth and reproduction.

Pharmacodynamics

Linezolid exhibits bacteriostatic activity against Enterococcus faecium and Staphylococcus aureus, and bactericidal activity against Streptococcus pneumoniae. Its unique mechanism of action helps in the treatment of resistant strains of bacteria, making it crucial for managing serious infections.

Pharmacokinetics

Linezolid is well-absorbed following oral administration, with an oral bioavailability of approximately 100%. It is widely distributed throughout the body, including the central nervous system. Linezolid is primarily metabolized in the liver, with excretion occurring mainly via the urine. The half-life is approximately 4 to 5 hours, allowing for twice-daily dosing.

Interactions

• beta 2 agonists + linezolid: Severe (increases risk of elevated blood pressure)
• buspirone + linezolid: Severe (increases risk of elevated blood pressure)
• levodopa + linezolid: Severe (increases risk of elevated blood pressure)
• methylphenidate + linezolid: Severe (increases risk of elevated blood pressure)
• ozanimod + linezolid: Severe (increases risk of a hypertensive crisis)
• reboxetine + linezolid: Severe (increases risk of a hypertensive crisis)
• sympathomimetics, vasoconstrictor (adrenaline/epinephrine, ephedrine, isometheptene, noradrenaline/norepinephrine, phenylephrine) + linezolid: Severe (increases risk of elevated blood pressure)
• pseudoephedrine + linezolid: Severe (increases risk of elevated blood pressure)
• bupropion + linezolid: Unknown (increases risk of intraoperative hypertension)
• MAO inhibitors + linezolid: Unknown (increases risk of adverse effects)

Pregnancy

The safety of linezolid in pregnancy has not been established. Use only if potential benefit justifies the potential risk to the fetus.

Breast-feeding

Linezolid is excreted in breast milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Dosage

Children: Refer to BNF for Children for appropriate dosing information.

Adults: Refer to BNF for appropriate dosing information.

Pregnancy

Consult a healthcare provider before use, as safety during pregnancy has not been well established.

Breast-feeding

Consult a healthcare provider before use, as it is not known if this drug is excreted in human milk.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Rabies prevention in individuals at high risk of exposure
• Post-exposure prophylaxis following potential rabies exposure
• Vaccination for travelers to endemic regions

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric patients.

Adults: Refer to the BNF for specific dosing guidelines, as it varies based on exposure risk and vaccination history.

Mechanism of action

The rabies vaccine works by stimulating the immune system to produce antibodies against the rabies virus. This is achieved through the introduction of inactivated or attenuated virus particles, which mimic the infection without causing the disease. The immune response generated helps to prevent the virus from causing illness upon subsequent exposure.

Pharmacodynamics

The rabies vaccine induces an adaptive immune response, leading to the production of neutralizing antibodies specific to the rabies virus. This immune memory protects against future infections. The vaccine is typically administered in a series of doses to ensure adequate immune response and long-term protection.

Pharmacokinetics

The pharmacokinetics of the rabies vaccine involve absorption at the injection site, followed by systemic distribution of the antigens. The onset of immunity generally occurs within two weeks after the initial vaccination, with peak antibody levels typically reached within one to two months. The duration of immunity can vary, necessitating booster doses in certain populations.

Interactions

• chloroquine+rabiesvaccine: Severe (decreases efficacy)

Pregnancy

Rabies vaccination is generally considered safe during pregnancy. However, the risks and benefits should be carefully evaluated.

Breast-feeding

Rabies vaccine is not known to cause any adverse effects in breastfeeding. However, consult with a healthcare provider for individual assessments.

Storage

Store the rabies vaccine in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Indications

• Allergic conditions
• Autoimmune diseases
• Inflammatory conditions
• Certain cancers
• Asthma exacerbations
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations, as these will depend on the child's age, weight, and specific clinical condition.

Adults: Refer to the specific BNF for appropriate dosing information based on the condition being treated. Dosage varies widely depending on the severity of the condition and the specific formulation used.

Mechanism of action

Dexamethasone binds to glucocorticoid receptors in the cytoplasm of target cells, leading to the formation of a receptor-hormone complex that translocates to the nucleus. This complex then modulates gene expression, resulting in the inhibition of pro-inflammatory cytokines and mediators, thus exerting potent anti-inflammatory and immunosuppressive effects.

Pharmacodynamics

Dexamethasone exhibits anti-inflammatory properties by reducing the migration of leukocytes and the production of cytokines. It suppresses the immune response and decreases capillary permeability, which helps in alleviating symptoms associated with inflammation. Its effects can be observed in various conditions, including autoimmune disorders, asthma, and as part of anti-cancer regimens.

Pharmacokinetics

Dexamethasone is rapidly absorbed when administered orally and reaches peak plasma concentrations within 1 to 2 hours. It has a high protein binding rate, primarily to albumin and corticosteroid-binding globulin. The drug is metabolized predominantly in the liver and has a half-life of approximately 3 to 4 hours. It is excreted mainly through urine as metabolites.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether vero is excreted in human milk. Caution should be exercised when administered to nursing women.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Mechanism of action

Cocaine produces anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. This is achieved by reversibly binding to and inactivating sodium channels. Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. Cocaine is the only local anesthetic with vasoconstrictive properties. This is a result of its blockade of norepinephrine reuptake in the autonomic nervous system. Cocaine binds differentially to the dopamine, serotonin, and norepinephrine transport proteins and directly prevents the re-uptake of dopamine, serotonin, and norepinephrine into pre-synaptic neurons. Its effect on dopamine levels is most responsible for the addictive property of cocaine. The presence and function of cannabinoid CB(2) receptors in the brain have been the subjects of much debate. /The investigators/ found that systemic, intranasal or intra-accumbens local administration of JWH133, a selective CB(2) receptor agonist, dose-dependently inhibited intravenous cocaine self-administration, cocaine-enhanced locomotion, and cocaine-enhanced accumbens extracellular dopamine in wild-type and CB(1) receptor knockout (CB(1)(-/-), also known as Cnr1(-/-)) mice, but not in CB(2)(-/-) (Cnr2(-/-)) mice. This inhibition was mimicked by GW405833, another CB(2) receptor agonist with a different chemical structure, and was blocked by AM630, a selective CB(2) receptor antagonist. Intra-accumbens administration of JWH133 alone dose-dependently decreased, whereas intra-accumbens administration of AM630 elevated, extracellular dopamine and locomotion in wild-type and CB(1)(-/-) mice, but not in CB(2)(-/-) mice. Intra-accumbens administration of AM630 also blocked the reduction in cocaine self-administration and extracellular dopamine produced by systemic administration of JWH133. These findings suggest that brain CB(2) receptors modulate cocaine's rewarding and locomotor-stimulating effects, likely by a dopamine-dependent mechanism. Cocaine hydrochloride is a local anesthetic which blocks initiation or conduction of nerve impulses following local application; when applied topically to mucous membranes, the drug also produces intense vasoconstriction. When applied topically to the mucous membranes of the nose or mouth, cocaine reduces the acuity of smell or taste, respectively. Cocaine exerts an indirect adrenergic effect by interfering with the uptake of norepinephrine by adrenergic nerve terminals, and therefore potentiates the effects of catecholamines. The indirect adrenergic effect is apparently the mechanism by which the drug produces vasoconstriction and mydriasis. Cocaine has CNS stimulating effects. The drug is also markedly pyrogenic, augmenting heat production by stimulating muscular activity and decreasing heat loss through vasoconstriction. Cocaine has multiple central and peripheral pharmacological actions. The action responsible for the rewarding property, and hence the abuse liability, of cocaine is an action in the dopaminergic synapse; in the rat the major set of critical dopaminergic synapses appears to be in the nucleus accumbens. Cocaine prolongs the activity of dopamine in the synapse by blocking the dopamine reuptake mechanism (which usually inactivates the transmitter by removing it from the proximity of its synaptic targets). This is an action shared with amphetamine; in addition to blocking the dopamine reuptake mechanism, amphetamine also augments dopaminergic function by augmenting dopamine release directly into the synapse. While amphetamine and cocaine have discriminable subjective effects, perhaps due to differences in rate of onset and metabolism or perhaps due to different side effects, cocaine shares its rewarding impact and abuse liability very closely with amphetamine. When drug access is unlimited, cocaine and amphetamine have the same ability to dominate behavior, reducing other beha

Pharmacodynamics

Cocaine is a local anesthetic indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.